As I see it

Share this article:
President Bush's nomination of Andrew von Eschenbach in March to be the FDA's permanent commissioner immediately ran into a brick wall. It rose in the form of Plan B, the ill-starred emergency contraceptive that the Bush administration has blocked from going over-the-counter.

The real story behind that block may never be known, but most knowledgeable observers agree it's a political payoff to religious conservatives whose support the president and his party still needs and who see the drug as either an abortifacient or as a likely catalyst of teenage promiscuity.

As his popularity sunk to record lows in March and Republicans on Capitol Hill showed signs of bolting in preparation for the November elections, Bush's Plan B block brought a counterblock from the left. Senators Patty Murray (D-WA) and Hillary Rodham Clinton (D-NY) said they would block von Eschenbach from a floor vote until the FDA makes a decision up or down on OTC Plan B.

The senators said they met with the nominee, and “he gave us no status and he couldn't give us any kind of timeline.” As they said this, the Senate chairman in charge of von Eschenbach's confirmation, Mike Enzi (R-WY), let it be known that he wants the White House to resolve the Plan B issue.

This is very unlikely to happen. Bush and his party can hardly afford to turn their backs on the religious right.  

There's a growing feeling that it doesn't matter whether the FDA has a permanent commissioner or not. After all, in the 64 months since Bush's inauguration, the FDA has had a confirmed commissioner for less than 12 and we've all survived. There's no public clamor for confirmation.

It's a Mexican standoff, and my bet is it will stay this way until the religious right blinks.

Dickinson is editor of Dickinson's FDA Webview (
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications